2-(二乙氨基)-N-(2,3-二甲基苯基)乙酰胺 | 142713-08-4

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-(二乙氨基)-N-(2,3-二甲基苯基)乙酰胺
• 中文别名: 利多卡因杂质F
• 英文名称: 2-(diethylamino)-N-(2,3-dimethyl-phenyl)acetamide
• 英文别名: N,N-diethyl-glycine-(2,3-dimethyl-anilide)；N,N-Diaethyl-glycin-(2,3-dimethyl-anilid)；2-diethylamine-2',3'-acetoxylidide；2-(diethylamino)-N-(2,3-dimethylphenyl)acetamide
• CAS: 142713-08-4
• 化学式: C₁₄H₂₂N₂O
• 分子量: 234.341
• InChiKey: VHNDUNVOBOZDQM-UHFFFAOYSA-N

物化性质

• 沸点：
  184 °C(Press: 4 Torr)
• 密度：
  1.026±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2,3-二甲基苯胺 在 sodium acetate 、 溶剂黄146 、 苯 作用下， 生成 2-(二乙氨基)-N-(2,3-二甲基苯基)乙酰胺
  参考文献：
  名称：

  Loefgren, Arkiv foer Kemi, 1946, vol. 22A, # 18, p. 11

  摘要：

  DOI：

文献信息

• Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action
  作者：Jorge C.S. Costa、Josiane S. Neves、Marcus V.N. de Souza、Rodrigo A. Siqueira、Nelilma C. Romeiro、Nubia Boechat、Patrícia M.R.e Silva、Marco A. Martins

  DOI：10.1016/j.bmcl.2007.11.122

  日期：2008.2

  relationship (SAR) study focused on chemical modifications of the structure of the local anesthetic lidocaine, and indicated analogues having reduced anesthetic potency, but with superior potency relative to the prototype in preventing anaphylactic or histamine-evoked ileum contraction. From the SAR analysis, 2-(diethylamino)-N-(trifluoromethyl-phenyl) and 2-(diethylamino)-N-(dimethyl-phenyl) acetamides were

  目前的结构-活性关系（SAR）研究集中于局部麻醉利多卡因结构的化学修饰，并指出麻醉药效价降低，但与原型药相比在预防过敏或组胺引起的回肠收缩方面的效价更高。从SAR分析中，选择2-（二乙基氨基）-N-（三氟甲基-苯基）和2-（二乙基氨基）-N-（二甲基-苯基）乙酰胺作为最有前途的化合物。提供了关于非麻醉性利多卡因衍生物作为变应性综合征药物发现模板的适用性的新见解。
• Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease
  申请人：Martins Marco Aurelio

  公开号：US20080221206A1

  公开（公告）日：2008-09-11

  The present invention relates to lidocaine derived compounds, which present less anesthetic activity than lidocaine itself, but with more anti-inflammatory and spasmolytic activity than said lidocaine as well as pharmaceutical compositions with at least one of these compounds or a salt of those as active principle and to the use of such compositions to treat, prevent or inhibit atopic diseases including asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance. The pharmaceutical composition may be available in spray form, solution, suspension, emulsion destinated to be applied by nebulization, or in any of the pharmaceutical available forms for oral or injectable use.
• US8163803B2
  申请人：——

  公开号：US8163803B2

  公开（公告）日：2012-04-24
• Loefgren, Arkiv foer Kemi, 1946, vol. 22A, # 18, p. 11
  作者：Loefgren

  DOI：——

  日期：——